B1

(12) UK Patent Application (19) GB (11) 2 192 633 (13) A

(43) Application published 20 Jan 1988

(21) Application No 8614468

(22) Date of filing 13 Jun 1986

(71) Applicant
Royal Postgraduate Medical School

(Incorporated in United Kingdom)

Hammersmith Hospital, Ducane Road, London W12 0HS

(72) Inventors
Jonathan Cohen
Calvin John Ryan

(74) Agent and/or Address for Service
Abel & Imray,
Northumberland House, 303–306 High Holborn, London WC1V 7LH

(51) INT CL⁴
C07K 17/00 // B01D 15/08 B01J 20/30 C07K 7/62

(52) Domestic classification (Edition J):
C3H K2
U1S 1356 1614 2410 C3H

(56) Documents cited
None

(58) Field of search
C3H
Selected US specifications from IPC sub-classes C07G C07K B01J

(54) Endotoxin removal

(57) An endotoxin sorbent comprises polymyxin B or a salt thereof immobilised on a solid phase support, said solid phase-polymyxin B sorbent having been treated with an anticoagulant capable of preventing or limiting the deposition of fibrin. Free anticoagulant binding sites are blocked.
The sorbent can be used in plasmapheresis apparatus.

GB 2 192 633 A

2192633

FIGURE 1

FIGURE 2

CON-Sepharose
PB-Sepharose

2192633

FIGURE 3

FIGURE 4

5|5

FIGURE 5

PLASMAPHERESIS ········●·····●···· PB-Sepharose
—●—●—●— CON-Sepharose

Plats x 10^9/L

600
400
200

0   1   2   3   4

Hours

SPECIFICATION

Endotoxin removal

5 The present invention relates to the removal of endotoxin from endotoxin-containing fluids.   5
  Endotoxin, which is part of the cell wall of gram negative bacteria, is implicated in gram-
negative bacteraemia. This occurs with a frequency of from 4 to 12 per 1000 hospital admis-
sions, and shock as a complication is seen in 16–44% of these cases. The precise pathogenesis
of gram-negative bacterial shock, also called septic shock, is unclear, but it is widely held that
10 endotoxin is responsible for many of its features. The overall mortality from septic shock is.   10
approximately 60% and has remained at this level for many years, despite improvements in
supportive care, more effective antimicrobial agents, the use of corticosteroids and other phar-
macological approaches.
  Endotoxin is also implicated in various other serious conditions including chronic and acute
15 liver disease, chronic and acute renal disease, radiation sickness and heat stroke.   15
  Polymyxin B is a cyclic polypeptide antibiotic which, in addition to its antimicrobial activity, has
been known for many years to have potent anti-endotoxin properties. Polymyxin B (PB) binds
stoichiometrically to endotoxin, and will neutralize many endotoxin-induced phenomena including
mouse lethality, intravascular coagulation, and the Shwartzman phenomenon. The use of poly-
20 myxin B for its anti-endotoxin (rather than anti-microbial) properties has been proposed but the   20
drug is unsuitable for repeated parenteral administration because it is both neurotoxic and
nephrotoxic.
  An alternative approach that has been proposed is to link polymyxin B to a solid phase
support and to use this as a specific sorbent. Polymyxin B has been linked to Sepharose (Trade
25 Mark) and also to polystyrene fibres, and such systems have been found to be capable in vitro   25
of removing endotoxin from endotoxin-containing solutions. The use of fibre-linked polymyxin B
has also been described in haemoperfusion of endotoxin-treated dogs, with improved survival in
the treated group. There are, however, a number of problems associated with haemoperfusion
which reduce its clinical applicability, in particular biocompatibility problems resulting from de-
30 struction of cellular elements in the blood (including platelets) during the passage of the blood   30
through the sorbent. The smaller the size of the sorbent particles, the greater is the problem of
cell destruction.
  The present invention is based on the surprising observation that plasmapheresis of endotoxin-
containing blood can be carried out successfully if a solid phase support carrying immobilised
35 polymyxin B is treated before use with an anticoagulant. This observation is surprising because   35
we have attempted to use polymyxin B linked to a solid phase support to remove endotoxin in
vivo using the technique of plasmapheresis, but such attempts have failed because of fibrin
deposition. This desposition generally starts in the sorbent column within 5 to 10 minutes of
starting plasmapheresis and within 15 to 20 minutes the plasmapheresis apparatus as a whole
40 becomes clogged to such an extent that it can no longer function effectively. The fibrin is   40
deposited throughout the plasmapheresis system, not just in the sorption column itself, and the
deposition occurs despite the presence of the heparin present conventionally in the circulating
plasma.
  The present invention provides an endotoxin sorbent comprising polymyxin B immobilised on a
45 solid phase support, the solid phase-polymyxin B sorbent having been treated with an anticoagu-   45
lant capable of preventing or limiting the deposition of fibrin to block free anticoagulant binding
sites.
  Polymyxin B may be used as such or in the form of a salt for example, the sulphate. Also
there may be used a mixture of any two or more components selected from polymyxin B and
50 salts thereof. Unless otherwise specified, the term "polymyxin B" is used herein to encompass   50
all such possibilities.
  The solid phase support may comprise any substance capable of immobilizing polymyxin B. It
is thought that in some cases at least polymyxin B can be bound to a support via an amino
group, and on this basis the support may be, for example, a solid material capable of forming a
55 covalent bond with an amino group. The polymyxin B may be immobilised on a solid support   55
either directly or via a coupling group. Accordingly, other suitable solid phase support materials
are those capable of accepting coupling groups suitable for the immobilisation of polymyxin B.
Examples of solid support materials are agarose and agarose derivatives, other carbohydrates,
polystyrene and regenerated cellulose.
60 The solid phase support may be used in any of a variety of physical forms, such as, for   60
example, those proposed for affinity chromatography in general, for example, beads, fibres,
webs, membranes and hollow fibres. Beads, for example, agarose beads, may be used in
columns. The size of beads preferred is generally in the range of from 45 to 165μ, but larger or
smaller beads may be used, longer columns generally being required with larger diameter beads.
65 Such bead size/column length parameters will be well-known to those skilled in the art of affinity   65

chromatography. Other physical forms of solid support, for example, fibres, for example, polysty-
rene fibres, webs, membranes and hollow fibres may be used analogously to their use in affinity
chromatography generally.

The anticoagulant used to treat that polymyxin B sorbent must be capable of preventing or
5   limiting the deposition of fibrin, either directly, that is to say, by influencing the conversion of   5
fibrinogen to fibrin, or indirectly, that is to say, by influencing any one or more of the other
steps involved in the intrinsic and extrinsic pathways of blood coagulation. Heparin is widely
used and known to be effective in preventing fibrin deposition. It is readily available, relatively
inexpensive, and substantially free from side effects. Accordingly, heparin is a preferred anti-
10 coagulant for the present invention, but any other anticoagulant having the property of interfering   10
with fibrin deposition may be used.

In the heparin-type category are, for example, low molecular weight heparin derivatives and
other heparin derivatives. Such derivatives may have advantages over native heparin, for
example, with regard to the specificity of their anti-fibrin-deposition activity. Thus, for example,
15 lower molecular weight derivatives may affect platelets less than native heparin does (see, for   15
example, Salzman E.W., Rosenberg R.D., Smith M.H., Linden J.N., and Savreau L., J. Clinical
Investigation (1981) 65 64–67). Other strongly acidic substances having a heparin-like anticoagu-
lant effect may be used, for example, dextran sulphate. Hirudin may also be used.

Antithrombotic agents directed towards different aspects of the haemostatic process may be
20 used as the anticoagulant, for example, inhibitors of intrinsic coagulation; and also platelet   20
aggregation inhibitors (antiplatelet agents), for example, adenyl compounds, for example, AMP
adenosine and 2-chloroadenosine; dipyridamole and lidoflazine; prostacyclin and prostaglandin E;
anti-inflammatory drugs, for example, aspirin, phenylbutazone, indomethacin, meclofenamate and
hydroxychloroquine; membrane stabilizers, for example, local anaesthetics and many antihista-
25 mines; serotonin antagonists; sulphydryl inhibitors, for example, N-ethylmaleimide and p-hydroxy-   25
mercuribenzoate; arginine esters and other guanidino compounds; various miscellaneous drugs
which inhibit platelet aggregation, for example, clofibrate, methylxanthines, and monoamine oxi-
dase inhibitors and also plasminogen activators, which enhance fibrinolysis, for example, plasmin,
streptokinase, and urokinase.

30 The present invention further provides a process for producing anticoagulant-treated, solid   30
phase-immobilised polymyxin B, which comprises immobilising polymyxin B on a solid phase
support and subsequently treating the solid phase support carrying polymyxin B with an anti-
coagulant capable of preventing or limiting fibrin deposition under conditions such that free
anticoagulant binding sites are blocked.

35 The anticoagulant treatment of the solid component may be carried out by incubating a sample   35
of the polymyxin B-bearing solid phase support with a predetermined volume of a solution
comprising the anticoagulant, or an anticoagulant-containing solution may be passed over and/or
through a sample of the polymyxin B-bearing solid phase component.

As indicated above, a wide variety of substances may be used as the solid phase support,
40 and polymyxin B may be immobilised on the support in a conventional manner. In the case of   40
agarose, available commercially as in bead form "Sepharose", the agarose is activated, for
example, using cyanogen bromide, and then reacted with polymyxin B, for example, according to
the method of Issekutz (J. Immunological Methods 61 (1983) 275–281). According to this
method, all reactions should be carried out in a pyrogen-free environment, that is to say, the
45 buffers and reagents should be prepared in a sterile fashion using pyrogen-free water, glass-ware   45
should be rendered as pyrogen-free as possible, and sterile plasticware should be used when-
ever practicable. Materials of the "Sepharose" type can be activated with cyanogen-bromide in a
conventional manner, or Sepharose itself can be obtained in activated form from the manufac-
turers (Pharmacia, Uppsala, Sweden). The activated material is generally swollen, washed, for
50 example, in 0.1 M HCl, and suspended in a suitable buffer, for example, a sodium bicarbonate   50
buffer, for example, 0.1 M NaHCO$_3$ containing 0.5 M NaCl, final pH 8.3. The resulting gel is
preferably allowed to settle, excess buffer removed, and then polymyxin B, generally in the form
of polymyxin B sulphate, is added to the gel, generally in the form of a solution in a buffer, for
example, as described above. The mixture of polymyxin B and the agarose material, for example,
55 Sepharose, is allowed to react for a suitable time, for example, overnight, at a temperature   55
generally between 0°C and room temperature, for example, in the range of from 2°C to 18°C,
for example, 4°C. Excess buffer is then generally discarded. At this stage it is conventional to
incubate the gel with an agent capable of blocking remaining reactive groups, for example,
ethanolamine.

60 In the case of other solid phase support materials, the polymyxin B may be immobilised in an   60
analogous or conventional manner. The immobilisation of polymyxin B on polystyrene fibres has
been described by Endo et al (Abstracts of the 14th International Congress of Chemotherapy
1985, Kyoto, Japan, Abstract P–40–9, International Society of Chemotherapy, active halogen
method), and also by Hanasawa et al (Therapeutic Aphersis: A critical look. Nose Y, Malchesky
65 P.S., Smith JW, ISAO Press, Cleveland 1984 pp 164–170).   65

As indicated above treatment of the solid phase support on which polymyxin B has been immobilised with the anticoagulant may be carried out by incubating the solid component with a solution comprising the anti-coagulant. A range of temperatures may be used, for example, from 2°C to 25°C, but room temperature is generally suitable.

5   The amount of anticoagulant used and the time of incubation is such that free anticoagulant   5
binding sites on the solid component are blocked. Clearly, the number of free anticoagulant binding sites will vary depending on the chemical constitution and physical form of the solid, and on the loading with polymyxin B. Having appreciated that the sites, and preferably as many as possible, should be blocked, it is a matter of simple trial and error to determine appropriate

10   amounts of anticoagulant and incubation times. It is generally convenient to use an excess,   10
preferably a considerable excess, of the anticoagulant compared with the amount generally incorporated in saline to prime plasmapheresis apparatus before use. In the case of heparin, this priming amount is generally within the range of from 5 to 20 units of heparin per ml of saline, for example, 10 units of heparin per ml.

15   As a guide, a suitable amount of anticoagulant in a plasmapheresis system for removing   15
endotoxin from blood where the anticoagulant is heparin, the solid phase is Sepharose 4B beads having a diameter within the range of from 45 to 165μ, and the amount of polymyxin B incubated with the Sepharose is 50 mg per 1.6 g dry weight, is 1,000 or more units of heparin per ml of Sehparose gel. Amounts of heparin as low as 100 units per ml of Sepharose gel wil

20   give satisfactory results for a short time but after 30 to 40 minutes fibrin deposition in the   20
extracorporeal circulation is observed. Accordingly, amounts of heparin in excess of 100 units per ml Sepharose gel are recommended, preferably 500 units or more, and especially 1,000 units or more, for example, 5,000 units or more, for example, 10,000 units.

The amounts of heparin required for other systems may be determined readily by simple trial

25   and error but, as indicated above, it is generally convenient to use an excess, and preferably a   25
large excess, and these considerations apply, mutatis mutandis, to other chosen anticoagulants.

As indicated above, instead of treating a batch of polymyxin B-bearing solid phase support with a predetermined volume of anticoagulant-containing solution, the solution may be passed over and/or through the batch of solid component. Again, the amount of anticoagulant to be

30   used may be determined by simple trial and error and the considerations given above with   30
regard to the amount of anticoagulant to be used also apply to present embodiment of the invention.

There is preferably used an excess, especially a large excess, of anticoagulants especially heparin compared with the amount generally incorporated in saline for the purpose of priming

35   plasmapheresis apparatus before use. The guide values given above for heparin may be fol-   35
lowed. The perfusion of the polymyxin B-bearing solid phase support with anticoagulant-contain-ing solution may be carried out as a separate step before incorporation of the treated material in plasmapheresis apparatus, or the perfusion may be carried out in situ in plasmapheresis apparatus before use, that is to say, before connection to the subject to be treated.

40   The resulting anticoagulant-treated endotoxin sorbent may be prepared in advance and stored   40
before use, for example, in pyrogen-free water containing a suitable preservative, for example, 25% (v/v) ethanol, or 0.2% (w/v) sodium azide, or it may be prepared as required, for example, in situ as described above.

As indicated above, the resulting anticoagulant-treated endotoxin sorbent may be incorporated

45   in suitable plasmapheresis apparatus, and the present invention also provides an endotoxin   45
sorbent according to the present invention in a form suitable for use in plasmapheresis appara-tus, for example, in a chromatography column, and the present invention further provides plasmapheresis apparatus including an anticoagulant-treated polymyxin B-carrying solid phase support according to the present invention.

50   Surgical techniques for the insertion into a body of lines suitable for the removal and return of   50
blood to be treated by plasmapheresis are known. The blood removed is generally pumped through a plasma separator within which the plasma is separated from the cellular components of the blood. In one method of plasmapheresis, the separated plasma is discarded, and the cellular components of the blood are returned to the body with replacement plasma or plasma

55   substitute. In another method, the separated plasma is passed through sorbent means compris-   55
ing a sorbent material to adsorb or absorb certain materials either non-specifically or specifically. The treated plasma is then reunited with the cellular blood components and returned to the body. The sorbent material may be a non-specific sorbent material, for example, powdered charcoal, or may comprise material suitable for affinity chromatography. The sorbent material is

60   conventionally present in the form of a column. Before carrying out plasmapheresis, the extracor- 60
poreal circuit should be primed with anticoagulant-containing solution, for example, heparin-containing saline, for example, saline containing 10 units of heparin per ml, or donor plasma containing 10 units of heparin per ml.

The present invention provides a method of removing endotoxin from endotoxin-containing

65   blood, which comprises separating plasma from the cellular components of the blood, and   65

treating the plasma with an endotoxin sorbent according to the present invention.

The separation of the plasma and its subsequent treatment with the endotoxin sorbent may be carried out in the same apparatus or the separated plasma may be treated in a separate endotoxin sorbent-containing apparatus.

5   The method of removing endotoxin from endotoxin-containing blood comprises, for example,   5
subjecting the blood to plasmapheresis in apparatus comprising anticoagulant-treated, polymyxin B-bearing solid phase support according to the present invention as a sorbent means.

The second method of plasmapheresis described above may be used in the present invention, that is to say, the method whereby the separated plasma is treated with sorbent means,

10   reunited with the cellular components and returned to the body. In this case, separated plasma   10
is treated "on line" with the sorbent means.

Alternatively, plasma may be separated from endotoxin-containing whole blood by plasmapheresis then treated on separate apparatus, for example, a column comprising an endotoxin sorbent according to the invention. The treated plasma may then if desired, be reunited with the cellular

15   components of the blood, before return to the body. The method of the present invention   15
includes both of these embodiments.

In plasmapheresis apparatus comprising sorbent means, the sorbent means may be any of the forms of anticoagulant-treated, polymyxin B-bearing solid phase support described above. The sorbent means is preferably in the form of a column, and the solid support is especially agarose

20   or polystyrene. The anticoagulant is especially heparin.   20

The sorbent means may be pre-treated with the same anticoagulant as is used to prime the extra-corporeal circuit, or a different anticoagulant may be used. It is preferable to use the same agent both for pre-treatment of the solid support and for priming the extra-corporeal circuit. Heparin is preferably used.

25   Alternatively, as indicated above, the sorbent means incorporated in the plasmapheresis appa-   25
ratus may be polymyxin B-bearing solid phase support that is treated *in situ* with anticoagulant. The amount of anticoagulant to be circulated through the solid component is indicated above, and should be an excess, especially a large excess compared with the amount of anticoagulant used conventionally for priming plasmapheresis apparatus, for example, in the case of heparin

30   with agarose beads (in the form of Sepharose 4B), amounts of heparin in excess of 100 units   30
per ml agarose gel are recommended, preferably 500 units or more, and especially 1,000 units or more, for example, 5,000 units or more, for example, 10,000 units.

The endotoxin-removal component of the plasmapheresis apparatus may be used in conjunction with one or more other components suitable for removing substances from plasma, either

35   specifically or non-specifically, that is to say, one or more other sorbent means. These other   35
components may be used in series or in parallel with the endotoxin-removing component.

Examples of components for removing other substances from plasma are activated charcoal, broadbased sorbents used in the treatment of acute poisoning, chronic and acute renal failure; particles suitable for the removal of non-polar solutes from polar media for example, plasma;

40   non-ionic macroreticular resins; sorbents with a particular attraction for lipid-soluble molecules;   40
anionic exchange resins; sorbents suitable for the removal of protein-bound solutes, for example, bound antibodies having a selective removal action; artificial cells; and immobilised or encapsulated enzymes.

In some cases, it may be possible to immobilise another sorbent, for example, certain of those

45   described above, on the same solid phase support as the polymyxin B. The present invention   45
includes such mixed sorbents.

After use, some or all of the endotoxin may be removed from the sorbent using certain buffer systems, for example, a solution containing deoxycholate, for example, 1% (w/v) deoxycholate, thus regenerating the 1% sorbent. For clinical use, however, it is advisable to use fresh rather

50   than regenerated sorbent material.   50

The efficacy of the anticoagulant-treated polymyxin B bearing solid phase support as sorbent in the removal of endotoxin can be tested *in vitro*. There are various assays which can be used for determining endotoxin levels, for example, those using Limulus amoebocyte lysate. There are various modifications of this assay, (see for example Cohen and McConnell (J. Infect. Dis 1984

55   *50* 916–924). Assay kits for Limulus amoebocyte lysate gelation tests are available commer-   55
cially.

Polymyxin B may be assayed in a conventional manner, for example, using the standard bioassay which employs Bordetella bronchiseptica ATCC 4617 (see Sullman S.C. Polymyxins In: Reeves D.S., Philips I., Williams J.D. and Wise R., Laboratory methods in antimicrobial chemo-

60   therapy, 1st Ed. Churchill-Livingstone, 1978, 232–234).   60

The assay methods described above may also be used in connection with plasmapheresis.

It has been found that the polymyxin B remains substantially immobilised on the solid phase support and is not eluted off during treatment of plasma. This is an important advantage, as polymyxin B is neurotoxic and nephrotoxic.

65   It will be appreciated that, although the invention has been described above in terms of   65

polymyxin B, it is applicable to all endotoxin sorbents. Accordingly, the present invention also
provides endotoxin sorbent immobilised on a solid phase support, the solid phase-endotoxin
sorbent having been treated with an anticoagulant capable of preventing or limiting fibrin despo-
sition, whereby free anticoagulant binding sites are blocked, apparatus comprising the sorbent
5 and a method of removing endtoxin from blood using the sorbent.   5
      The following Examples illustrate the present invention. In the Examples, percentages are
calculated as w/v, unless otherwise specified.

Example 1
10 a. Preparation of PB-Sepharose. (Polymyxin B-Sepharose).   10
      The method described by Issekutz *(loc cit)* was followed. Sterile pyrogen-free plasticware was
used whenever practicable. Glassware was washed thoroughly and heated at 160°C overnight
before use. All buffers and reagents were prepared in a sterile fashion and were pyrogen-free,
1.6 g of cyanogen bromide activated Sepharose 4B (Pharmacia, Uppsala, Sweden) was washed
15 extensively in 1 mM HCl and then resuspended in coupling buffer (0.1 M $NaHCO_3$ containing 0.5   15
M NaCl, final pH 8.3.) The gel was allowed to settle, and excess buffer was removed and
replaced with 2.5 ml of the above coupling buffer containing 50 mg of PB (Calmic Medical,
London England). (For control columns, PB was omitted). The tube containing the Sepharose was
then sealed and incubated at 4°C, for 18 hours on a mechanical rotator. Next, the gel was
20 centrifuged at 80 g and excess buffer removed. Ten-ml of 1 M ethanolamine pH7 were added   20
and the tube incubated for 2 hours at room temperature. After further gentle centrifugation the
supernatant was removed and the gel washed in three alternating cycles of acetate buffer (0.1
M sodium acetate with 0.5 M NaCl, final pH 4.0) and borate buffer (0.1 M sodium tetraborate
with 0.5 M NaCl final pH 8.0). Finally, the gel was incubated on a rotary mixer for 1.5 hours at
25 room temperature with heparinized sterile 0.9% saline using 10,000 units of heparin per ml of   25
gel. The treated gel was washed with 0.9% saline and was stored at 4°C in 0.9% saline
containing 0.02% sodium azide.

   b. Endotoxin assay.
30   There was used a modified quantitative chromogenic Limulus amoebocyte lysate (LAL) assay,   30
as described previously (Cohen and McConnell, *loc cit*). This method was further modified; the
lysate was used at a 1 in 10 dilution in pyrogen-free water of the strength recommended by the
manufacturers. (MA Bioproducts, Walkersville, Md, USA). The chromogenic substrate was
S2423 (Kabi Diagnostica, Stockholm, Sweden).
35   35
   c. Polymyxin B assay.
      A standard bioassay which employs *Bordetella bronchiseptica* ATCC 4617 (Sullmann S.C. *loc
cit*) was used.

40 d. Experimental procedure.   40
      One millilitre of PB-Sepharose (or antibiotic-free control Sepharose: CON-Sepharose) was
washed with 20 ml of 0.9% saline and incubated for 30 minutes at room temperature with
5000 mg of endotoxin derived from *Escherichia coli* 0127: B8 (Sigma, Poole, Dorset UK). The
suspension was placed in a 2 ml sterile plastic syringe pre-packed with a small wad of glass
45 wool. The column was washed with sterile 0.9% saline and six sequential 1 ml fractions   45
collected over 30 minutes. The amount of endotoxin in each fraction was determined as
described above. The experiment was carried out five times for both PB-Sepharose and CON-
Sepharose.
      Additionally, 10 ml of 0.9% saline were run three times through PB-Sepharose or CON-
50 Sepharose columns, then bioassayed for PB.   50

Example 2
a. Plasmapheresis.
      The surgical technique for insertion of indwelling carotid arterial and jugular venous lines,
55 allowing perfusion in the unrestrained and conscious state was as previously described (Ryan   55
C.J., Pusey C.D., Aslam M, Gaylor J.D., Maini R., and Courtney J.M., Artificial Organs Vol. 10,
No. 2, 135–144 (1986).
      Plasmapheresis apparatus is described, by way of example only, with reference to *Figure 1,*
which is a diagrammatic representation. A rat 1 to which indwelling carotid arterial and jugular
60 venous lines 2 and 3 respectively had been inserted was kept in a container 4 and given food 60
and water *ad libitum*. The arterial blood is pumped, by a pump 5, through a specially designed
plasma separator into a reservoir 7. The filtered plasma is pumped by a pump 8 through a
column 9 containing the sorbent material. The treated plasma is then reunited with the cellular
blood components in a mixing means 10 and returned pumped by pump 11 to the animal via
65 jugular vein lines. Using a 3 pump system trans-membrane pressure can be maintained at less   65

than 50 mmHg with a filtration rate of 0.2–0.22 ml/min. By these means, one complete plasma
volume (approximately 11–12 ml) can be treated in 50–60 minutes. The extracorporeal circuit is
primed with approximately 3 ml of heparinized saline, obviating the need for donor blood or
plasma. Previous studies in 15 normal animals have established that the system can be used
5   repeatedly with no apparent side effects, nor marked effects on red cell, leucocyte or platelet   5
counts. A sieving coefficient of >98% for the plasma membrane was obtained for C3, IgC and
albumen.

b.   Clearance of endotoxin.
10   Two groups of 3 rats were studied. Twenty-one hours following cannulation, lead acetate 50   10
mg/kg was given intravenously (Selye H., Tuchweber B., and Bertok L., J. Bact. (1966) *91*
884–890), and 45 minutes later the animals received endotoxin 10 μg/kg intra-arterially. After a
further 15 minutes plasmapheresis as described in (a) above was begun and continued for 90
minutes, in one group using PB-Sepharose columns and in the other, CON-Sepherose. Plasma
15   samples for endotoxin measurement were obtained simultaneously from 3-way tape [10 and 11]   15
placed immediately beneath ('pre') and above ('post') the column, respectively.
To determine the effect of the lead acetate, two rats were studied as described above, except
that they received 1 ml of 0.9% saline instead of endotoxin. Serial blood samples were ob-
tained, and the animals were observed for 24 hours. In addition, an aliquot of each plasma
20   sample was mixed *in vitro* with endotoxin to give a fixed final concentration of 50 ng/ml. These   20
samples were assayed to determine if plasma containing lead acetate inhibited the detection of
endotoxin in the LAL assay.

c.   Effects of endotoxin removal.
25   An additional two groups of 4 rats received lead acetate and endotoxin as described above   25
and then underwent plasmapheresis as described above using either PB-Sepharose or CON-
Sepharose columns. Blood samples were obtained prior to injection of endotoxin, immediately
before plasmapheresis, and at intervals thereafter for estimation of haemoglobin, packed cell
volume and leucocyte count using a Coulter Counter model 2F; platelet counts were determined
30   manually. The animals were observed for 24 hours.   30
Plasma from four PB-Sepharose perfused animals was used to determine if PB was eluted
from the column *in vivo*. Samples obtained at 5, 10 and 15 minutes and at 90, 120 and 240
minutes were pooled and assayed for PB as described.

35   d.   *Statistical methods*   35
In vitro clearance of endotoxin on PB-Sepharose or CON-Sepharose colums was compared by
Students' T-test. The effect of plasmapheresis on leucocyte and platelet counts was examined
by analysis of variance.

40   e.   *Results*   40
(1).   *In vitro* studies.
Figure 2 illustrates the cumulative recovery of endotoxin in 6 x 1 fractions collected from CON-
Sepharose and PB-Sepharose columns. Twenty-four per cent of the challenge dose (5,000 ng)
remained on the control column, compared to 94% on the PB-Sepharose column (p=0.05).
45   There was no detectable anti-microbial activity in the 0.9% saline washed through the PB-   45
Sepharose column. The *B. bronchiseptica* assay could detect 10 μ/ml of PB.

(2).   *In vivo* studies.
Plasma endotoxin levels measured 'pre' and 'post' the PB-Sepharose and CON-Sepharose
50   columns after injection of 10mg/g endotoxin followed by plasmapheresis are shown in *Figure 3*.   50
In the control animals, the peak level reached at 20 minutes was 260 ng/ml. The 'pre' and
'post' column endotoxin levels were the same, indicating that there was no significant endotoxin
clearance across the CON-Sepharose column. In animals perfused over PB-Sepharose, the peak
'pre' column level, which occurred at 30 minutes, was 50 ng/ml. Moreover, the peak 'post'
55   column endotoxin concentration was 13 ng/ml, and for most of the remainder of the experiment   55
was undetectable. It is of interest that endotoxin was present continually in 'pre' column
samples from PB-Sepharose treated animals, despite the fact that endotoxin was undetectable in
'post' column samples for most of the experiment. Thus, the absorbent was effectively remov-
ing the endotoxin presented to it, but it appeared that further endotoxin (albeit at a low level)
60   was being generated from the animal. The most plausible explanation is that this 'fresh' endo-   60
toxin is derived from the intestinal microflora.
Control animals that received lead acetate alone remained well throughout 24 hours of obser-
vation, and serial blood samples revealed no change in haemoglobin, leucocyte or platelet
counts. The presence of lead acetate in the plasma did not impair endotoxin detection in the
65   LAL assay (data not shown). Pooled plasma samples from 4 PB-Sepharose animals contained no   65

detectable PB activity.

The effect of PB-Sepharose perfusion on endotoxin-induced leucopenia is shown in *Figure 4.* The total leucocyte count fell from $7:15 \pm 3.9 \times 10^9/L$ immediately prior to plasmapheresis, to $6.25 \pm 1.5 \times 10^9/L$ after 4 hours. In animals perfused over CON-Sepharose, the leucocyte count
5 fell from $5.7 \pm 1.3 \times 10^9/1$ to $2.5 \pm 1.0 \times 10^9/L$ (p 0.01).   5

Figure 5 illustrates the effect of the procedure on the platelet count. Animals perfused over the PB-Sepharose were protected substantially from thrombocytopenia: the initial count was $550 \pm 37 \times 10^9/L$, and it fell to $430 \pm 29 \times 10^9/L$. In control animals, the count fell from $546 \pm 130 \times 10^9/L$ to $108 \pm 45 \times 10^9/L$ (p 0.001)
10 All four control animals died 5–10 hours after the procedure began. In contrast, all four   10
animals perfused over PB-Sepharose survived the 24 hour observation period.

Unequivocal evidence was obtained to show that the PB-Sepharose-treated animals were protected from endotoxin-induced leucopenia, thrombocytopenia and death.

It was important to establish if these observations were indeed the result of selective endo-
15 toxin removal or whether there could be an alternative explanation, in particular, whether PB was   15
leaking from the column and neutralizing the endotoxin in the fluid phase. Using a sensitive bioassay for PB, there was found no detectable antimicrobial activity either in eluates obtained after extensive *in vitro* washing, or in pooled plasma samples from animals perfused over PB-Sepharose. The possibility cannot be excluded that very small amounts of PB were eluted from
20 the column, but if so the antibiotic would be present at concentrations considerably less than   20
the typical peak serum level of 2–8 mg/l (20–$80,000$ μ/l).

CLAIMS
1. An endotoxin sorbent comprising polymyxin B or a salt thereof immobilised on a solid
25 phase supprt, the solid phase-polymyxin B sorbent having been treated with an anticoagulant   25
capable of preventing or limiting the deposition of fibrin, whereby free anticoagulant binding sites are blocked.
2. An endotoxin sorbent as claimed in claim 1, wherein the anticoagulant as heparin, a low molecular weight heparin derivative, or hirudin.
30   3. An endotoxin sorbent as claimed in claim 1, wherein the anticoagulant is an inhibitor of   30
intrinsic coagulation, a platelet aggregation inhibitor, or a plasminogen activator.
4. An endotoxin sorbent as claimed in any one of claims 1 to 3, wherein the solid phase support is a material capable of forming a covalent bond with an amino group, or capable of accepting a coupling group suitable for the immobilisation of polymyxin B.
35   5. An endotoxin sorbent as claimed in any one of claims 1 to 3, wherein the solid phase   35
support is agarose or a derivative thereof.
6. An endotoxin sorbent as claimed in any one of claims 1 to 3, wherein the solid phase support is polystyrene.
7. An endotoxin sorbent as claimed in any one of claims 1 to 6, wherein the solid phase
40 support is in the form of beads, fibres, hollow fibres, webs or membranes.   40
8. An endotoxin sorbent as claimed in claim 1, wherein the solid phase support is agarose and the anticoagulant is heparin.
9. An endotoxin sorbent as claimed in claim 1, substantially as described in Example 1 herein.
45   10. A process for producing an endotoxin sorbent as claimed in claim 1, which comprises   45
immobilising polymyxin B or a salt thereof on a solid phase support, and subsequently treating the solid phase support carrying polymyxin B or a salt thereof with an anticoagulant capable of preventing or limiting the deposition of fibrin, under conditions such that free anticoagulant-binding sites are blocked.
50   11. A process as claimed in claim 10, wherein the solid phase support carrying polymyxin B   50
is incubated with a predetermined volume of a solution comprising the anticoagulant.
12. A process as claimed in claim 10, wherein a solution comprising the anticoagulant is passed over and/or through the solid phase support carrying polymyxin B or a salt thereof.
13. A process as claimed in any one of claims 10 to 12, wherein the solid phase support is
55 as defined in any one of claims 4 to 7.   55
14. A process as claimed in any one of claims 10 to 13, wherein the anticoagulant is as defined in claim 2 or claim 3.
15. A process as claimed in claim 10, claim 11 or claim 12, wherein the solid phase support is agarose and the anticoagulant is heparin.
60   16. A process as claimed in claim 10, carried out substantially as described in Example 1 or   60
Example 2 herein.
17. An endotoxin sorbent as claimed in claim 1, whenever produced by a process as claimed in any one of claims 10 to 16.
18. An endotoxin sorbent as claimed in any one of claims 1 to 9 or claim 17 in a column
65 suitable for use in plasmapheresis or affinity chromatography apparatus.   65

19. An endotoxin sorbent as claimed in claim 18, substantially as described in Example 2 herein.

20. Plasmapheresis apparatus which includes an endotoxin sorbent as claimed in any one of claims 1 to 9 and 17 to 19.

21. Plasmapheresis apparatus as claimed in claim 20, wherein the endotoxin sorbent is produced *in situ* by passing a solution comprising the anticoagulant over and/or through the solid phase support carrying immobilised polymyxin B or a salt thereof to block anticoagulant binding sites.

22. Plasmapheresis apparatus as claimed in claim 20 or claim 21, which also comprises one or more other sorbents.

23. Plasmapheresis apparatus as claimed in claim 22, wherein the other sorbent is or are selected from activated charcoal; broad-based sorbents used in the treatment of acute poisoning or chronic or acute renal or liver disease; particles suitable for the removal of non-polar solutes from plasma; non-ionic macroreticular resins; sorbents having a particular attraction for lipid-soluble molecules; anionic exchange resins; sorbents suitable for the removal of protein-bound solutes; immunoadsorbents; and immobilised encapsulated enzymes.

24. Plasmapheresis apparatus as claimed in claim 22 or claim 23, wherein the other sorbent means is in series or in parallel with the endotoxin sorbent, or is carried on the same solid phase support as the polymyxin B.

25. Plasmapheresis apparatus substantially as described herein with reference to, and as illustrated by, Fig. 1 of the accompanying drawings.

26. Endotoxin sorbent immobilised silicon immobilised on a solid phase support, the solid phase-endotoxin sorbent having been treated with an anticoagulant capable of preventing or limiting fibrin deposition, whereby free anticoagulant binding sites are blocked.